Director/PDMR Shareholding
GSK plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Lynn Baxter
b)
Position/status
President, Europe
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
James Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
David Redfern
b)
Position/status
President, Corporate Development
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Regis Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Philip Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Deborah Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
7 (partnership shares)
£18.8393
7 (matching shares)
d)
Aggregated information
Aggregated volume Price
14 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Victoria Whyte
b)
Position/status
SVP & Company Secretary
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
6 (partnership shares)
£18.8393
6 (matching shares)
d)
Aggregated information
Aggregated volume Price
12 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Neil Falkingham
b)
Position/status
PCA of Lynn Baxter (President, Europe)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£18.8393
6 (partnership shares)
£18.8393
6 (matching shares)
d)
Aggregated information
Aggregated volume Price
12 Ordinary Shares
£18.8393
e)
Date of the transaction
2026-06-09
f)
Place of the transaction
London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHSFLFEFEMSEIM
Recent news on GSK
See all newsBrief: GSK Says Momelotinib Granted Orphan Drug Designation In US And EU For Vexas Syndrome
Director/PDMR Shareholding
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal (updated)
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
Director/PDMR Shareholding